In brief
- An analysis of the 2024 US National Survey on Drug Use and Health (NSDUH) finds no association between psilocybin use and a decrease in depression treatment.
- Among 6,793 people with a recent major depressive episode, 7.3% had used psilocybin in the past year.
- Those who used it reported more unmet care needs: 52.0% compared to 33.9%.
A common concern regarding psilocybin is that individuals with depression might abandon medical follow-ups or medication due to a reliance on mushrooms. A study published in Psychological Medicine and released on October 6 by the University of California San Diego put this idea to the test using general population data, and the results contradict that fear.
What was measured and with what data
The team, led by Avery Eun (UC San Diego School of Medicine) alongside Kevin H. Yang (UCLA) and Joseph J. Palamar (New York University), worked with the 2024 US National Survey on Drug Use and Health (NSDUH). This is a representative population survey, and that edition was the first to ask not only if psilocybin had ever been used, but when.
The sample consisted of 6,793 people aged 12 and older who had experienced a major depressive episode in the past year. Of these, an estimated 7.3% used psilocybin during that same period. The researchers compared this group to the rest on three fronts: outpatient, inpatient, or telemedicine treatment, and the use of prescription drugs for depression.
The findings: no withdrawal from care
Using psilocybin was not associated with receiving less treatment on any of those fronts, nor with taking less prescribed medication. In other words, people who turn to mushrooms continue to see doctors and therapists at a frequency comparable to those who do not use them. “People who use psilocybin are not abandoning conventional mental health care, and that is good news,” summarized Eun.
The profile is also informative: according to the university’s press release, the group that used psilocybin was younger, included more men, more single people, and more individuals employed full-time.
The uncomfortable data: more unmet needs
The other half of the results points to a different part of the problem. 52.0% of those who used psilocybin reported having an unmet mental health care need, compared to 33.9% of those who did not. The authors hypothesize—though it remains to be proven—that dissatisfaction with what the system offers pushes some people to seek other paths on their own, including psychedelics. It is a plausible reading, but the survey does not allow for a definitive conclusion.
Limitations to keep in mind
This is a cross-sectional study: it captures a moment in time and cannot determine causality. “Unmet need” is a self-reported perception, not a clinical measure, and the survey does not report on dosage, context of use, or symptom outcomes. Furthermore, use outside of clinical trials lacks the structured dosing and psychological support found in studies, so the safety and efficacy data from those trials cannot be directly applied. It functions as a snapshot of behaviors, not an evaluation of the substance’s effect. If you want broader context on the substance, we have a guide to psilocybin and magic mushrooms.
What it implies
The finding dismantles a frequently repeated argument—that people replace medical care with mushrooms—at least according to the metrics of this survey. For those treating people with depression, the authors suggest stopping the assumption that there is a withdrawal from care and instead asking openly about use, without judgment, because that conversation allows for better support. It is the same spirit of harm reduction and responsible use: starting from what the person is actually doing and their right to decide about their own mind, while providing information and resources. The gap in unmet needs, however, is a signal for services: something they are offering is not reaching those who are seeking alternatives.
Source
- Miles Martin / UC San Diego Today. Contrary to Fears, Psilocybin Users with Depression Continue to Seek Treatment (regarding Eun, Yang, and Palamar, “Psilocybin use, mental health treatment utilization, and unmet treatment need among US individuals with depression”). UC San Diego Today, October 6, 2026.
Educational content written from a harm reduction perspective and with respect for individual freedom. It is not a substitute for advice from a healthcare professional and is not intended to encourage or condemn any drug use.
